Liu Haitao, Bo Yu, Gao Pengcheng, Li Zhizhong, Qiu Shaodong, Feng Gangning, Yang Zongqiang, Zhang He, Mi Zhanhu
Department of Traumatic Orthopedics, General Hospital of Ningxia Medical University, Yinchaun, Ningxia, China.
Ningxia Medical University, Yinchaun, Ningxia, China.
J Mater Sci Mater Med. 2025 Sep 2;36(1):71. doi: 10.1007/s10856-025-06912-4.
In this study, vancomycin, bone cement (PMMA) and mineralized collagen (MC) were mixed in order to obtain a new composite drug-carrying biomaterial, which has good results in both drug slow release, good biocompatibility, and good growth of osteoblasts, osteoclasts, and mesenchymal stem cells on the surface of the biomaterial, which provides a new therapeutic idea for the clinical treatment of bone defect infections. In this study, the drug retardation system of vancomycin and mineralized collagen composite bone cement-carrying biomaterials was prepared in proportion to the drug retardation system, and the experimental studies were carried out using electron microscope scanning, HPLC drug retardation analysis, in vitro antimicrobials, and co-cultivation of osteoclasts, osteoblasts, and mesenchymal stem cells. We found that the composite drug-carrying material of vancomycin, bone cement and mineralized collagen had good slow-release effect and antimicrobial properties, and the addition of vancomycin and bone cement to mineralized collagen material had even better drug-release efficiency than that of bone cement plus vancomycin alone. In vitro antimicrobial showed that the composite material has excellent antimicrobial effect against Staphylococcus aureus. Co-culture of osteoblasts, osteoclasts and mesenchymal stem cells with the material showed that the cells were morphologically complete on the surface of the composites with good growth status. Vancomycin, bone cement and mineralized collagen composite drug-carrying biomaterials have excellent slow-release effect and antimicrobial properties with good biocompatibility, which is a new therapeutic idea for the future clinical treatment of bone defect infections.
在本研究中，将万古霉素、骨水泥（聚甲基丙烯酸甲酯）和矿化胶原混合，以获得一种新型载药生物材料，该材料在药物缓释、良好的生物相容性以及生物材料表面成骨细胞、破骨细胞和间充质干细胞的良好生长方面均有良好效果，为骨缺损感染的临床治疗提供了一种新的治疗思路。在本研究中，按照药物缓释体系制备了万古霉素与矿化胶原复合载骨水泥生物材料的药物缓释体系，并采用电子显微镜扫描、高效液相色谱药物缓释分析、体外抗菌以及破骨细胞、成骨细胞和间充质干细胞共培养等进行实验研究。我们发现，万古霉素、骨水泥和矿化胶原的复合载药材料具有良好的缓释效果和抗菌性能，在矿化胶原材料中添加万古霉素和骨水泥的载药效率甚至比单独添加骨水泥和万古霉素更好。体外抗菌实验表明，该复合材料对金黄色葡萄球菌具有优异的抗菌效果。成骨细胞、破骨细胞和间充质干细胞与该材料共培养显示，细胞在复合材料表面形态完整，生长状态良好。万古霉素、骨水泥和矿化胶原复合载药生物材料具有优异的缓释效果和抗菌性能以及良好的生物相容性，是未来骨缺损感染临床治疗的一种新的治疗思路。
